- Home
- Publications
- Publication Search
- Publication Details
Title
Novel systemic therapy for hepatocellular carcinoma
Authors
Keywords
-
Journal
Hepatology International
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-14
DOI
10.1007/s12072-020-10073-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
- (2020) L.-T. Chen et al. ANNALS OF ONCOLOGY
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of locoregional therapies in the wake of systemic therapy
- (2020) Daniel H. Palmer et al. JOURNAL OF HEPATOLOGY
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
- (2020) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.
- (2020) Stephen Lam Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
- (2020) Ahmed Omar Kaseb et al. JOURNAL OF CLINICAL ONCOLOGY
- Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
- (2020) Feng Bi et al. JOURNAL OF CLINICAL ONCOLOGY
- Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
- (2020) Qiu Li et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
- (2020) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
- (2020) Aung Naing et al. Journal for ImmunoTherapy of Cancer
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology
- (2019) Bishal Gyawali et al. JAMA Oncology
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
- (2019) Max W. Sung et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib
- (2019) Álvaro Díaz-González et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
- (2019) Emerson Y. Chen et al. JAMA Internal Medicine
- Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
- (2019) MinKe He et al. JAMA Oncology
- Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
- (2019) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
- (2019) Thomas Yau et al. JOURNAL OF HEPATOLOGY
- Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
- (2019) Tanios S Bekaii-Saab et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA7Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
- (2019) C-H Hsu et al. ANNALS OF ONCOLOGY
- Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma
- (2019) Ying-Chun Shen et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
- (2018) D. H. Palmer et al. BRITISH JOURNAL OF CANCER
- Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)
- (2018) Lori J. Wirth et al. CANCER
- Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
- (2018) Chun Jye Lim et al. GUT
- SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
- (2018) Pierce K.H. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
- (2018) Yingjun Xie et al. Journal of Immunology Research
- Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma
- (2018) Da-Liang Ou et al. Liver Cancer
- A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
- (2018) Chia-Jui Yen et al. Liver Cancer
- Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion
- (2018) Sang Min Yoon et al. JAMA Oncology
- Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial
- (2018) Masatoshi Kudo Liver Cancer
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
- (2018) Tim F. Greten et al. GASTROENTEROLOGY
- Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy
- (2018) Renumathy Dhanasekaran et al. GASTROENTEROLOGY
- Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
- (2018) Yu-Yang Lin et al. SEMINARS IN LIVER DISEASE
- Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
- (2018) Cheng Xu et al. BMJ-British Medical Journal
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
- (2017) Toshiyuki Tamai et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study
- (2017) Clarence Yen et al. Liver Cancer
- Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
- (2016) Ann-Lii Cheng et al. HEPATOLOGY
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
- (2015) Y.-K. Kang et al. ANNALS OF ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration
- (2014) Robert Shumaker et al. JOURNAL OF CLINICAL PHARMACOLOGY
- GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
- (2013) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started